<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03540420</url>
  </required_header>
  <id_info>
    <org_study_id>2017-11-03BHG</org_study_id>
    <secondary_id>2017-004572-62</secondary_id>
    <nct_id>NCT03540420</nct_id>
  </id_info>
  <brief_title>Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer</brief_title>
  <acronym>ACHILES</acronym>
  <official_title>A Randomized Phase II Study Comparing Atezolizumab After Concurrent Chemo-radiotherapy With Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norwegian University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Alesund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Akershus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Nord-Trøndelag HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Haukeland University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sorlandet Hospital HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Molde Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nordlandssykehuset HF</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Volda Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kristiansund Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ôrebro University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gävle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Linkoeping</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute, Lithuania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Winterthur KSW</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Basel, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Inselspital, Berne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Graubünden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Freiburger Spital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik Hirslanden, Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kantonsspital Olten</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Spital STS AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ente Ospedaliero Cantonale, Bellinzona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cantonal Hospital of St. Gallen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Olavs Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Isala</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zuyderland Medisch Centrum</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Netherlands Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Amphia Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medisch Spectrum Twente</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Norwegian University of Science and Technology</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some patients with limited disease small-cell lung cancer (LD SCLC) are cured after&#xD;
      chemo-radiotherapy, but the majority relapse and die from their cancer. Better therapy is&#xD;
      needed. Immunotherapy represents the largest advance in cancer therapy in recent years and&#xD;
      has demonstrated promising activity in SCLC. In this study we will investigate whether&#xD;
      atezolizumab prolongs survival in LD SCLC patients who have undergone chemo-radiotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have&#xD;
&#xD;
        -  completed 4 course of platinum/etoposide and thoracic radiotherapy of 45 Gy/30&#xD;
           fractions, 2 fractions per day&#xD;
&#xD;
        -  non-progression after chemo-radiotherapy&#xD;
&#xD;
        -  ECOG performance status 0-2&#xD;
&#xD;
      will be randomized to receive atezolizumab 1200 mg IV every 3 weeks in 12 months or standard&#xD;
      of care (observation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2018</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>2 year survival</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best response rate during study treatment period</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment-related adverse events as assessed by CTCAE v5.0</measure>
    <time_frame>13 months after last patient completed atezolizumab therapy</time_frame>
    <description>The number of mild (grade 1-2), severe (grade 3-4) and fatal (grade 5) events during the chemoradiotherapy will be reported for the whole study cohort.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported Health related quality of life on the EORTC QLQ-C30 and LC13 questionnaires.</measure>
    <time_frame>2 year after enrollment is completed</time_frame>
    <description>Patients will report HRQoL before and after chemoradiotherapy and then at each evaluation the first 2 years. Mean scores will be compared at each timepoint. A difference of 10 points or more is considered clinically relevant.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">212</enrollment>
  <condition>Small-cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Atezolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>atezolizumab after completed chemo-radiotherapy and non-progression</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard care after completed chemo-radiotherapy and non-progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab</intervention_name>
    <description>atezolizumab 1200 mg intravenous every 3 weeks in 12 months</description>
    <arm_group_label>Atezolizumab</arm_group_label>
    <other_name>anti-PDL1</other_name>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed small-cell lung cancer&#xD;
&#xD;
          -  Previous radiotherapy to the thorax is allowed as long as the patient can receive TRT&#xD;
             of 45 Gy.&#xD;
&#xD;
          -  Stage I-III according to TNM v8 ineligible for surgery provided all lesions can be&#xD;
             included in a tolerable radiotherapy field (&quot;limited disease&quot;)&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Measureable disease according to the RECIST 1.1&#xD;
&#xD;
          -  Adequate organ function defined as: (a) Serum alanine transaminase (ALT) ≤ 2.5 x upper&#xD;
             limit of normal (ULN); (b) Total serum bilirubin ≤ 1.5 x ULN; (c)Absolute neutrophil&#xD;
             count (ANC) ≥ 1.5 x 10 superscr 9/L; (d) Platelets ≥ 100 x 10 superscr 9/L ; (e)&#xD;
             Creatinine &lt; 100 µmol/L and calculated creatinine-clearance &gt; 50 ml/min. If calculated&#xD;
             creatinine-clearance is &lt; 50 ml/min, an EDTA clearance should be performed&#xD;
&#xD;
          -  No malignant cells in pericardial or pleural fluid (at least 1 sample should be&#xD;
             obtained if pleural fluid is present) If there is so little fluid that it cannot&#xD;
             easily be collected, the patient is considered eligible.&#xD;
&#xD;
          -  Pulmonary function: FEV1 &gt; 1 l or &gt; 30 % of predicted value and DLCO &gt; 30 % of&#xD;
             predicted value&#xD;
&#xD;
          -  Female patients of childbearing potential (Postmenarcheal, not postmenopausal (&gt;12&#xD;
             continuous months of amenorrhea with no identified cause other than menopause), and no&#xD;
             surgical sterilization) should use highly effective contraception and take active&#xD;
             measures to avoid pregnancy while undergoing atezolizumab treatment and for at least 5&#xD;
             months after the last dose. Birth control methods considered to be highly effective&#xD;
             are listed in Appendix D of the protocol&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  previous systemic therapy for SCLC or immune checkpoint blockade therapy&#xD;
&#xD;
          -  serious concomitant systemic disorders (for example active infection, unstable&#xD;
             cardiovascular disease) which in the opinion of the investigator would compromise the&#xD;
             patient's ability to complete the study, or would interfere with the evaluation of the&#xD;
             efficacy and safety of the study treatment&#xD;
&#xD;
          -  lung disease requiring systemic steroids in doses of &gt;10 mg prednisolone (or&#xD;
             equivalent dose of other steroid)&#xD;
&#xD;
          -  previous allogeneic or organ transplant&#xD;
&#xD;
          -  active or history of autoimmune disease or immune deficiency, including, but not&#xD;
             limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid&#xD;
             antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome,&#xD;
             or multiple sclerosis&#xD;
&#xD;
          -  history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis&#xD;
             obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of&#xD;
             active pneumonitis on screening chest computed tomography (CT) scan&#xD;
&#xD;
          -  live vaccine administered in the last 30 days&#xD;
&#xD;
          -  active infection requiring IV antibiotics&#xD;
&#xD;
          -  active viral hepatitis or HIV-positive&#xD;
&#xD;
          -  conditions - medical, social, psychological - which could prevent adequate information&#xD;
             and follow-up&#xD;
&#xD;
          -  clinically active cancer other than SCLC with the exception of malignancies with a&#xD;
             negligible risk of metastases or death (e.g. 5-years OS rate of &gt;90%), such as&#xD;
             adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma,&#xD;
             localized prostate cancer, ductal carcinoma in situ, or stage I uterine cancer.&#xD;
             Hormonal therapy for non-metastatic prostate or breast cancer is allowed.&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Torstein B Rø, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Norwegian University of Science and Technology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bjørn H Grønberg, MD, PhD</last_name>
    <phone>+47 47297878</phone>
    <email>bjorn.h.gronberg@ntnu.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trude C Frøseth, MSc</last_name>
    <email>Trude.Camilla.Salvesen.Froseth@stolav.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Aalborg Universitetshospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Mcculloch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>København</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seppo Langer</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tine Schytte</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saulius Cicenas</last_name>
    </contact>
    <contact_backup>
      <last_name>Vaida Gedvilaite</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Antoni van Leeuwenhoek Ziekenhuis</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Willemijn Theelen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rijnstate Ziekenhuis</name>
      <address>
        <city>Arnhem</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Claessens</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cor van der Leest</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medische Centrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hugo Schouwink</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joachim Aerts</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zuyderland Ziekenhuis</name>
      <address>
        <city>Sittard</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frank LJ Custers</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antonius Ziekenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisanne Kastelijn</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Isala Ziekenhuis</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jos Stigt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haukeland Universitetssykehus</name>
      <address>
        <city>Bergen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne Aanerud</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Drammen sykehus - Vestre Viken</name>
      <address>
        <city>Drammen</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odd Terje Brustugun</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Haugesund hospital</name>
      <address>
        <city>Haugesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sverre Fluge</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sørlandet Sykehus</name>
      <address>
        <city>Kristiansand</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guri Hoven</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset i Kristansund</name>
      <address>
        <city>Kristiansund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magnus Gryt</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sykehuset Levanger</name>
      <address>
        <city>Levanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hanne Sorger</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Molde Sjukehus</name>
      <address>
        <city>Molde</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kjersti Torgersen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Akershus Universitetssykehus AHUS</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Siri Glørsen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital Ullevål</name>
      <address>
        <city>Oslo</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Moksnes Bjaanes</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Petersen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssykehuset Nord-Norge</name>
      <address>
        <city>Tromsø</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Helbekkmo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Clinic at St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjørn Henning Grønberg, md prof</last_name>
      <email>bjorn.h.gronberg@ntnu.no</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Volda hospital</name>
      <address>
        <city>Volda</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Odd F Aasen</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ålesund Hospital</name>
      <address>
        <city>Ålesund</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Øyvind Yksnøy</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gävle hospital</name>
      <address>
        <city>Gävle</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Isaksson</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhus</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Inger Storaker</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Linköping</name>
      <address>
        <city>Linköping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Vikström</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skånes University Hospital</name>
      <address>
        <city>Lund</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Planck</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georgios Tsakonas</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitetssjukhuset Örebro</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erik Lundin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sacha Rothschild</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Scherz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Inselspital</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amina Scherz</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Mark</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten - Solothurner Spitäler</name>
      <address>
        <city>Olten</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Walter Mingrone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cantonal Hospital of St. Gallen</name>
      <address>
        <city>St Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Appenzeller</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Spital STS AG</name>
      <address>
        <city>Thun</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Ackermann</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miklos Pless</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirslanden Klinik</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas von Briel</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>Norway</country>
    <country>Sweden</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 16, 2018</study_first_submitted>
  <study_first_submitted_qc>May 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2018</study_first_posted>
  <last_update_submitted>December 10, 2020</last_update_submitted>
  <last_update_submitted_qc>December 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atezolizumab</keyword>
  <keyword>Chemoradiotherapy</keyword>
  <keyword>Immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

